NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-265-2011-0-CH-18 Anti-CD22 Chimeric Antigen Receptors CH EP 12781544.7 Abandoned
NEI E-769-2013-0-PCT-02 Treatment Of AMD With IL-17RC Receptor Or Other IL-17 Blockade PCT PCT PCT/US2014/034538 Expired
NCI E-220-2011-0-US-06 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER US National Stage 14/352,096 9168266 Issued PDF
NCI E-212-2011-0-US-03 Monospecific And Bispecific Human Monoclonal Antibodies Targeting Insulin-Like Growth Factor II (IGF-II) US National Stage 14/352,312 9127056 Abandoned PDF
NCI E-074-2007-0-JP-15 BRACHYURY POLYPEPTIDES AND METHODS OF USE JP DIV 2014-083444 Issued
NIA E-092-2011-0-JP-07 The Use Of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine And Other Stereoismeric Dehydro And Hydroxylated Metabolites Of (R,S)-ketamine In The Treatment Of Depression And Neuropathic Pain JP National Stage 2014-535975 Issued
NCI E-220-2011-0-GB-09 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER GB EP 12841601.3 Issued
NCI E-220-2011-0-FR-08 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER FR EP 12841601.3 Issued
NCI E-220-2011-0-DE-07 HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER DE EP 12841601.3 Issued
NEI E-169-2008-0-US-07 Methods of Using Interferon Gamma to Absorb Fluid from the Subretinal Space US CON 14/252,489 9486502 Issued PDF
NCI E-024-2009-0-US-09 Gene Signature For Predicting Prognosis Of Patients With Solid Tumors US DIV 14/252,005 9394358 Issued PDF
NIA E-092-2011-0-US-08 THE USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN US National Stage 14/351,441 9650352 Issued PDF
NCI E-265-2011-0-BR-04 Anti-CD22 Chimeric Antigen Receptors BR National Stage BR112014008849-7 Abandoned
NCATS E-234-2012-0-PH-22 PAK Inhibitors For the Treatment of Fragile X Syndrome PH National Stage 1-2014-500956 Pending
NCI E-139-2007-0-US-10 Methods And Compositions For Detecting Immune Responses US DIV 14/247,372 Abandoned
NCATS E-287-2011-0-RU-14 Amido Compounds As RORgt Modulators And Uses Thereof RU National Stage 2014113926 Pending
NIAID E-153-2015-0-US-01 Antiviral Compounds Effective Against SARS and MERS Coronavirus US 61/976,031 Abandoned
NCI E-116-2014-0-US-01 Iodonium Analogs As Inhibitors Of NADPH Oxidases And Other Flavin Dehydrogenases; Formulations Thereof; And Uses Thereof US 61/976,362 Abandoned
NHLBI E-051-2019-0-US-02 Improved Image Contrast In Inversion MfR Imaging, Improved Workflow And Inter-scan Reliabilibity In MRI Myocardial Viability Imaging US ORD 14/245,011 9734573 Issued PDF
NCI E-227-2006-5-AU-09 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS AU DIV 2014201936 Issued
NIAID E-189-2011-2-CN-02 Treatment And Prevention Of Diseases Mediated By Microorganisms via Drug-Mediated Manipulation of the Eicosanoid Balance CN National Stage 201280049137.5 Pending
NCATS E-287-2011-0-BR-04 Amido Compounds As RORgt Modulators And Uses Thereof BR National Stage BR112014005268-9 Abandoned
NCI E-109-2014-0-US-01 Use of GTF2I Mutations in the Prognosis of Thymic Cancers US 61/975,222 Abandoned
NCI E-192-2008-1-US-04 Expression of IL-12 Family Heterodimers US DIV 14/244,768 9546202 Issued PDF
NCI E-217-2011-0-US-03 Genetic Marker For Predicting Prognosis In Patients Infected With Hepatitis C Virus US National Stage 14/349,395 Abandoned
NIDDK E-284-2008-0-US-10 Low Molecular Weight Thyroid Stimulating Hormone Receptor (TSHR) Agonists US CON 14/243,821 9296729 Issued PDF
NHGRI E-116-2011-0-US-04 Method of Treating Pathologic Heterotopic Ossification US National Stage 14/130,220 Abandoned
NCI E-065-2014-0-US-01 Use Of RNA Splicing Inhibitors To Overcome Drug Resistance US 61/974,378 Abandoned
NCI E-080-2014-0-US-01 ZIRCONIUM-89 OXINE COMPLEX AS A CELL LABELING AGENT FOR POSITRON EMISSION TOMOGRAPHY US 61/973,706 Abandoned
NICHD E-271-2011-0-US-03 Influenza Vaccine US National Stage 14/348,321 Abandoned
NIAMS E-042-2005-0-US-04 Mechanoactive Microfluidic Imaging Bioreactor US CON 14/221,984 Abandoned
NHLBI E-124-2014-0-US-01 Device For Closure Of Transvascular Or Transcameral Access Ports US 61/971,458 Abandoned
NCI E-147-2012-2-US-02 Methods Of Treating Periodontal Inflammation And Periodontal Bone Loss US National Stage 14/347,434 Abandoned
NIAID E-032-2011-0-US-05 Multivalent Vaccines for Rabies Virus and Filoviruses US National Stage 13/983,545 10849975 Issued PDF
NIMH E-156-2006-0-US-05 Beta-amyloid PET Imaging Agents US DIV 14/223,782 Abandoned
NIAID E-293-2011-2-US-06 Novel Influenza Hemagglutinin Protein-Based Vaccines US National Stage 14/346,849 9441019 Issued PDF
NCI E-104-2013-0-PCT-02 Anti-CD276 Polypeptides, Proteins, and Chimeric Antigen Receptors PCT PCT PCT/US2014/031543 Expired
NIA E-012-2012-0-US-08 Combined IVIG And C1 Inhibitor Therapy For Neurological Disorders US National Stage 14/346,478 10471142 Issued PDF
NCI E-043-2009-0-US-04 T-Cell Receptors and Related Materials and Methods of Use US DIV 14/221,823 9688739 Abandoned PDF
NCATS E-240-2011-0-US-02 Galactokinase Inhibitors For The Treatment and Prevention of Associated Diseases and Disorders US National Stage 14/346,400 9447087 Issued PDF
NINDS E-249-2011-0-US-04 Method of Treating Multiple Sclerosis By Intrathecal DEpletion of B Cells and Biomarkers to Select Patients with PRogressive Multiple Sclerosis US National Stage 14/346,473 Abandoned
CC E-088-2014-0-US-01 Conductive and Retrievable Devices US 61/968,757 Abandoned
NIDCR E-142-2011-0-US-05 AAV MEDIATED EXENDIN-4 GENE TRANSFER TO SALIVARY GLANDS TO PROTECT SUBJECTS FROM DIABETES OR OBESITY US National Stage 14/112,790 9511103 Issued PDF
NIA E-051-2008-0-US-08 Compositions and Methods for Delivering Inhibitory Oligonucleotides US CON 14/220,726 9415116 Issued PDF
NCI E-106-2014-0-CA-06 YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA CA National Stage 2907560 Issued
NCI E-106-2014-0-CN-07 YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA CN National Stage 201480028312.1 Issued
NCI E-106-2014-0-MX-12 YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA MX National Stage MX/a/2015/013380 Issued
NCI E-106-2014-0-EP-08 YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA EP National Stage 14797995.9 Issued
NCI E-106-2014-0-DE-19 YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA DE EP 14797995.9 Issued
NCI E-106-2014-0-FR-20 YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA FR EP 14797995.9 Issued